Founder & Chairman
Shin Hatou,
M.D., Ph.D.
MEMBER INTRODUCTIONS
MANAGEMENT TEAM
- 1998
- Keio University, M.D.
- 2002
- Research Assistant, Keio University (Ophthalmology)
- 2008
- Assistant Professor, Keio University (Ophthalmology)
- 2013
- Specially Appointed Lecturer, Keio University (Ophthalmology)
- 2015
- Founder & CEO, Cellusion
- 2025
- Chairman, Cellusion
CEO
Takuya Kaneko,
LL.M.
- 1998
- The Export-Import Bank of Japan
(currently Japan Bank for International Cooperation) - 2006
- Morgan Stanley Japan Securities
(currently Mitsubishi UFJ Morgan Stanley Securities) - 2017
- Executive Director, Mitsubishi UFJ Morgan Stanley Securities
- 2022
- CFO, Cellusion
- 2023
- CFO, Executive Officer, Cellusion
- 2024
- CFO, Board Director, Cellusion
- 2025
- CEO, Cellusion
Head, Legal & Compliance Dept.
SHINOBU TAKEMURA, Patent Attorney
- 2000
- Hitachi Software Engineering (currently Hitachi Solutions)
- 2006
- Oncolys BioPharma
- 2008
- SBI Intechstra
- 2011
- Oji Paper (currently Oji Holdings)
- 2019
- YAMASHIN-FILTER
- 2022
- Director, IP & Legal Department, Cellusion
- 2024
- Executive Officer, Head, Legal & Compliance Dept, Cellusion
OUTSIDE DIRECTORS
Outside Director
Tomokatsu Hongo,
Ph.D.
- 2006
- Summit Pharmaceuticals International Corporation (SPI)
- 2010
- Head of Biology Group, SPI
- 2016
- Executive Officer, Keio Innovation Initiative (-present)
- 2017
- Outside Director, Cellusion
Outside Director
Hiroaki Kobayashi,
M.D., MBA
- 2010
- Physician, The University of Tokyo Hospital and Hitachi General Hospital
- 2014
- Medical Director, Japanese Organization for Medical Device Development
- 2018
- Manager, Boston Scientific Corporation Japan
- 2019
- Principal, The University of Tokyo Edge Capital Partners
- 2021
- Outside Corporate Auditor, Cellusion
- 2023
- Outside Director, Cellusion
- 2024
- Partner, The University of Tokyo Edge Capital Partners (-present)
Outside Director
Yoshiharu Asai
- 2010
- Daiwa Securities Capital Markets Co. Ltd. (currently Daiwa Securities Co. Ltd.)
- 2018
- Innovation Network Corporation of Japan (currently INCJ, Ltd.)
- 2020
- Principal, JIC Venture Growth Investments Co., Ltd. (-present)
- 2023
- Outside Director, Cellusion
Outside Director
Tomotaka Goji, MBA, Ph.D.
- 1996
- Ministry of International Trade and Industry (currently The Ministry of Economy, Trade and Industry)
- 2004
- The University of Tokyo Edge Capital Co., Ltd.
- 2015
- Managing Director, Japan Venture Capital Association
- 2018
- CEO and President, Managing Partner, The University of Tokyo Edge Capital Partners Co., Ltd. (-present)
- 2022
- Vice Chairman, Japan Venture Capital Association
- 2023
- Chairman, Japan Venture Capital Association (-present)
- 2023
- Outside Corporate Auditor, Cellusion
- 2025
- Outside Director, Cellusion
Outside Director
Hisashi Mitsuguchi
- 2008
- Development Bank of Japan Inc.
- 2014
- DBJ Capital Co.
- 2019
- Development Bank of Japan Inc.
- 2023
- DBJ Capital K.K. (-present)
- 2025
- Outside Director, Cellusion
CORPORATE AUDITORS
Outside Corporate Auditor
Hiromi Furushima
- 1994
- The Legislative Bureau of the House of Representatives
- 1997
- KOGA & PARTNERS
- 2000
- Nishimura & Partners (currently Nishimura & Asahi)
- 2006
- Ito & Mitomi (currently Morrison Foerster)
- 2011
- Novartis Holding Japan K.K
- 2012
- Head, Legal & Compliance Office, SANDOZ K.K.
- 2014
- Head of Pharma Legal Department, Novartis Pharma K.K.
- 2016
- Corporate Officer, General Counsel, Head of Legal & IP and Country Legal Head, Novartis Pharma K.K.
- 2022
- Director, International Legal, Alnylam Japan K.K. (-present)
- 2022
- Outside Director, PRISM BioLab Co.,Ltd. (-present)
- 2023
- Outside Corporate Auditor, Cellusion
ADVISORS
Management Advisor
Joji Hayashida,
MBA, Ph.D.
CEO and Representative Partner, Acmex Partners, LLC
After working for MSKCC, Astellas Pharma, and Celusion as Executive Vice President COO, he became independent. He has been involved in business in the biotech industry for over 15 years.
- Memorial Sloan-Kettering Cancer Center
- Astellas Pharma Inc.
- Cellusion, Inc.
- Acmex Partners, LLC
R&D Advisor
Yoshinori Shinoki
Has been involved in numerous clinical development projects for leading global pharmaceutical companies and CROs. Currently serves as CEO of his own consulting firm, Pharma Initiative Support
- Parexel
- Eli Lilly
Management Advisor
Shunta Ide
Has over 30 years experience in the financial industry, including as Executive Officer, SMBC Nikko Securities, Managing Director, Morgan Stanley MUFG Securities, and at The Bank of Tokyo-Mitsubishi. Currently serves as CEO of his own consulting firm, KOMABA Planning
- SMBC Nikko Securities
- Morgan Stanley MUFG Securities
- Morgan Stanley
- The Bank of Tokyo-Mitsubishi
PR Advisor
Wataru Amano,
MBA
Has extensive experience in corporate branding and promotion having worked at PR companies, including Signal and Parco Digital Marketing. Former COO of Vector group company, Signal
- PARCO
- VECTOR
- PERSOL CAREER
- Light
